Tirzepatide Mechanism of Action: Dual GIP/GLP-1 Agonism in Research

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the “twincretin” that sits between semaglutide (GLP-1 selective) and retatrutide (triple agonist) in the incretin spectrum.

The twincretin design

Component	Role
GLP-1 agonism	Appetite suppression, insulin secretion, slowed gastric emptying
GIP agonism	Incretin effect, fat-tissue signaling, additional insulinotropic drive
C20 fatty-diacid tail	Albumin binding → extended half-life, once-weekly dosing

Tirzepatide is a 39-amino-acid peptide engineered from the native GIP sequence, with the fatty-diacid moiety conjugated through a hydrophilic linker. That lipidization is the same strategy used in retatrutide’s design.

Why the GIP arm matters

GIP (glucose-dependent insulinotropic polypeptide) signaling adds an incretin contribution beyond GLP-1 alone — in fat tissue and in glucose-dependent insulin secretion. The dual-agonist hypothesis is that GIP amplifies the GLP-1-driven effects, which is why tirzepatide is the reference compound for dual-incretin pharmacology studies.

Research applications

• GIP/GLP-1 receptor co-activation and signaling studies
• Comparative incretin pharmacology (vs semaglutide, vs retatrutide)
• Metabolic pathway research (glucose homeostasis, lipid metabolism)
• Reference standard for dual-agonist assays

Reference data

CAS 2023788-19-2 · C225H348N48O68 · MW 4813.5 · 10 mg lyophilized vial · 99.3% purity

Store at -20°C, reconstitute with bacteriostatic water — see semaglutide vs tirzepatide and retatrutide vs tirzepatide for the class comparisons.